The CenterWatch Weekly, March 20, 2017
Scott Gottlieb trumps competition as FDA Commissioner nominee
President Trump’s choice of Scott Gottlieb, M.D., a conservative health policy expert and venture capitalist, to lead the FDA has drawn wide support from the drug industry, yet the nominee may face scrutiny on Capitol Hill over potential conflicts of interest. Gottlieb, a medical doctor and former FDA deputy commissioner, serves on the board of several biopharmaceutical companies and has received more than $400,000 in payments from drugmakers in the last few years.
Keapstone Therapeutics created as new virtual biotech for Parkinson’s
The University of Sheffield and Parkinson’s UK have combined forces to create Keapstone Therapeutics. The goal of the newly formed company is to help move research into nuclear factor erythroid 2-related factor 2 (Nrf2) through the development process and, hopefully, into testable treatments for Parkinson’s disease. Parkinson’s disease affects around 1 million people in the U.S. and 127,000 in the U.K.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information